460 related articles for article (PubMed ID: 14520384)
1. Increasing number of companies found ineligible for SBIR funding.
Bouchie A
Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
[No Abstract] [Full Text] [Related]
2. Chasing biotech, state by state--winners and losers.
Wilan KH
Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
[No Abstract] [Full Text] [Related]
3. Little science, big bucks.
DeFrancesco L
Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
[No Abstract] [Full Text] [Related]
4. Biotech parks proliferate, despite concerns over sustainability.
Jia H; Jayaraman KS; Orellana C
Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
[No Abstract] [Full Text] [Related]
5. Mind the (biomedical funding) gap.
Klausner A
Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
[No Abstract] [Full Text] [Related]
6. Benefits of biotech clusters questioned.
Sheridan C
Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
[No Abstract] [Full Text] [Related]
7. VC funding hits high in Q1.
Lawrence S
Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825
[No Abstract] [Full Text] [Related]
8. Boutiques reborn in 2003.
Surendran A
Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
[No Abstract] [Full Text] [Related]
9. The YIC factor.
Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
[No Abstract] [Full Text] [Related]
10. Biotech IPOs--flop or pop?
Jacobs T
Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
[No Abstract] [Full Text] [Related]
11. Looking at US versus European exit opportunities.
Lawrence S
Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
[No Abstract] [Full Text] [Related]
12. Germany biotech gets second chance.
Sheridan C
Nat Biotechnol; 2003 Dec; 21(12):1414-5. PubMed ID: 14647310
[No Abstract] [Full Text] [Related]
13. The rise of European venture capital for biotechnology.
Howell M; Trull M; Dibner MD
Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
[No Abstract] [Full Text] [Related]
14. Mixed results in Q1.
Lawrence S
Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
[No Abstract] [Full Text] [Related]
15. Life support for life science innovation?
Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
[TBL] [Abstract][Full Text] [Related]
16. The importance of angels in starting a US biotech venture.
Sohl J
Nat Biotechnol; 2005 Feb; 23(2):263-4. PubMed ID: 15724275
[No Abstract] [Full Text] [Related]
17. 2006: a stellar year for financing.
Lawrence S
Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
[No Abstract] [Full Text] [Related]
18. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
Schmidt E
Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
[No Abstract] [Full Text] [Related]
19. India aims to become the main bioinformatics hub.
Jayaraman KS; Louët S
Nat Biotechnol; 2004 Aug; 22(8):933. PubMed ID: 15286632
[No Abstract] [Full Text] [Related]
20. Japanese firms broaden investment focus to early biotech.
Louët S; Sipp D
Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
[No Abstract] [Full Text] [Related]
[Next] [New Search]
